EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · IEX Real-Time Price · USD
8.87
-0.80 (-8.27%)
Jul 18, 2024, 3:28 PM EDT - Market open

EyePoint Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2002
Revenue
50.0246.0241.436.9434.4420.37
Upgrade
Revenue Growth (YoY)
25.70%11.14%12.09%7.27%69.10%587.77%
Upgrade
Cost of Revenue
4.754.638.338.185.822.69
Upgrade
Gross Profit
45.2741.3933.0828.7628.6117.68
Upgrade
Selling, General & Admin
50.9251.7960.3253.0846.0247.71
Upgrade
Research & Development
81.1864.6649.6428.517.4215.37
Upgrade
Other Operating Expenses
0022.752.462.462.46
Upgrade
Operating Expenses
132.1116.45132.7284.0465.965.54
Upgrade
Operating Income
-86.83-75.07-99.64-55.28-37.29-47.86
Upgrade
Interest Expense / Income
0.441.253.195.57.266.18
Upgrade
Other Expense / Income
-8.44-5.6-0.57-2.360.852.76
Upgrade
Pretax Income
-78.83-70.71-102.25-58.42-45.39-56.79
Upgrade
Income Tax
0.080.080000
Upgrade
Net Income
-78.92-70.8-102.25-58.42-45.39-56.79
Upgrade
Shares Outstanding (Basic)
533937291310
Upgrade
Shares Outstanding (Diluted)
533937291310
Upgrade
Shares Change
41.15%4.25%29.76%124.04%23.06%125.65%
Upgrade
EPS (Basic)
-1.81-1.82-2.74-2.03-3.54-5.44
Upgrade
EPS (Diluted)
-1.81-1.82-2.74-2.03-3.54-5.44
Upgrade
Free Cash Flow
-16.65-1.61-67.16-50.25-14.8-56.91
Upgrade
Free Cash Flow Per Share
-0.32-0.04-1.80-1.75-1.15-5.46
Upgrade
Gross Margin
90.50%89.93%79.89%77.86%83.09%86.81%
Upgrade
Operating Margin
-173.60%-163.13%-240.65%-149.64%-108.28%-235.02%
Upgrade
Profit Margin
-157.77%-153.84%-246.97%-158.14%-131.82%-278.88%
Upgrade
Free Cash Flow Margin
-33.30%-3.49%-162.19%-136.04%-42.97%-279.46%
Upgrade
EBITDA
-77.74-69-96.62-50.15-35.49-48.01
Upgrade
EBITDA Margin
-155.41%-149.94%-233.36%-135.76%-103.05%-235.76%
Upgrade
Depreciation & Amortization
0.660.462.452.772.652.6
Upgrade
EBIT
-78.4-69.47-99.07-52.92-38.14-50.62
Upgrade
EBIT Margin
-156.73%-150.95%-239.26%-143.26%-110.74%-248.55%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).